MedKoo Cat#: 112063 | Name: PAz-PC
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. PAz-PC is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.

Chemical Structure

PAz-PC
PAz-PC
CAS#117746-89-1

Theoretical Analysis

MedKoo Cat#: 112063

Name: PAz-PC

CAS#: 117746-89-1

Chemical Formula: C33H64NO10P

Exact Mass: 665.4268

Molecular Weight: 665.85

Elemental Analysis: C, 59.53; H, 9.69; N, 2.10; O, 24.03; P, 4.65

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Azelaoyl PC; 1-Palmitoyl-2-Azelaoyl PC; PAz-PC
IUPAC/Chemical Name
(R)-2-((8-carboxyoctanoyl)oxy)-3-(palmitoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
InChi Key
GHQQYDSARXURNG-SSEXGKCCSA-N
InChi Code
InChI=1S/C33H64NO10P/c1-5-6-7-8-9-10-11-12-13-14-15-18-21-24-32(37)41-28-30(29-43-45(39,40)42-27-26-34(2,3)4)44-33(38)25-22-19-16-17-20-23-31(35)36/h30H,5-29H2,1-4H3,(H-,35,36,39,40)/t30-/m1/s1
SMILES Code
CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCC(O)=O)=O)COP([O-])(OCC[N+](C)(C)C)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
DMF 1.0 1.50
DMSO 5.0 7.51
Ethanol 30.0 45.06
PBS (pH: 7.2) 5.0 7.51
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 665.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Karki P, Li Y, Zhang CO, Ke Y, Promnares K, Birukova AA, Eggerman TL, Bocharov AV, Birukov KG. Amphipathic Helical Peptide L37pA Protects against Lung Vascular Endothelial Dysfunction Caused by Truncated Oxidized Phospholipids via Antagonism with CD36 Receptor. Am J Respir Cell Mol Biol. 2024 Jan;70(1):11-25. doi: 10.1165/rcmb.2023-0127OC. PMID: 37725486; PMCID: PMC10768836. 2: Ke Y, Karki P, Li Y, Promnares K, Zhang CO, Eggerman TL, Bocharov AV, Birukova AA, Birukov KG. Aging-Related Accumulation of Truncated Oxidized Phospholipids Augments Infectious Lung Injury and Endothelial Dysfunction via Cluster of Differentiation 36-Dependent Mechanism. Cells. 2023 Jul 26;12(15):1937. doi: 10.3390/cells12151937. PMID: 37566016; PMCID: PMC10416939. 3: Karki P, Zhang CO, Promnares K, Li Y, Ke Y, Birukova AA, Birukov KG. Truncated oxidized phospholipids exacerbate endothelial dysfunction and lung injury caused by bacterial pathogens. Cell Signal. 2023 Sep;109:110804. doi: 10.1016/j.cellsig.2023.110804. Epub 2023 Jul 10. PMID: 37437826; PMCID: PMC10544726. 4: Bouzayene A, Zaffaroullah R, Bailly J, Ciceron L, Sarrasin V, Cojean S, Argy N, Houzé S, Joste V; French National Malaria Reference Centre study group. Evaluation of two commercial kits and two laboratory-developed qPCR assays compared to LAMP for molecular diagnosis of malaria. Malar J. 2022 Jun 27;21(1):204. doi: 10.1186/s12936-022-04219-1. PMID: 35761324; PMCID: PMC9238120. 5: Martin-Blondel G, Lescure FX, Assoumou L, Charpentier C, Chapplain JM, Perpoint T, Grouteau G, Cordel H, Pialoux G, Pacanowski J, Thy M, Bauvois A, Laureillard D, Hamrouni F, Algarte-Genin M, Poissy J, Descamps D, Costagliola D; CoCliCo Study Group. Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study. BMC Infect Dis. 2022 Jun 13;22(1):540. doi: 10.1186/s12879-022-07508-x. PMID: 35698029; PMCID: PMC9189443. 6: Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler- Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. PMID: 35113714. 7: Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, Michailidis E, Hoffmann HH, Eto S, Garcia-Prat M, Bizien L, Parra-Martínez A, Yang R, Haljasmägi L, Migaud M, Särekannu K, Maslovskaja J, de Prost N, Tandjaoui- Lambiotte Y, Luyt CE, Amador-Borrero B, Gaudet A, Poissy J, Morel P, Richard P, Cognasse F, Troya J, Trouillet-Assant S, Belot A, Saker K, Garçon P, Rivière JG, Lagier JC, Gentile S, Rosen LB, Shaw E, Morio T, Tanaka J, Dalmau D, Tharaux PL, Sene D, Stepanian A, Megarbane B, Triantafyllia V, Fekkar A, Heath JR, Franco JL, Anaya JM, Solé-Violán J, Imberti L, Biondi A, Bonfanti P, Castagnoli R, Delmonte OM, Zhang Y, Snow AL, Holland SM, Biggs C, Moncada-Vélez M, Arias AA, Lorenzo L, Boucherit S, Coulibaly B, Anglicheau D, Planas AM, Haerynck F, Duvlis S, Nussbaum RL, Ozcelik T, Keles S, Bousfiha AA, El Bakkouri J, Ramirez-Santana C, Paul S, Pan-Hammarström Q, Hammarström L, Dupont A, Kurolap A, Metz CN, Aiuti A, Casari G, Lampasona V, Ciceri F, Barreiros LA, Dominguez-Garrido E, Vidigal M, Zatz M, van de Beek D, Sahanic S, Tancevski I, Stepanovskyy Y, Boyarchuk O, Nukui Y, Tsumura M, Vidaur L, Tangye SG, Burrel S, Duffy D, Quintana-Murci L, Klocperk A, Kann NY, Shcherbina A, Lau YL, Leung D, Coulongeat M, Marlet J, Koning R, Reyes LF, Chauvineau-Grenier A, Venet F, Monneret G, Nussenzweig MC, Arrestier R, Boudhabhay I, Baris-Feldman H, Hagin D, Wauters J, Meyts I, Dyer AH, Kennelly SP, Bourke NM, Halwani R, Sharif-Askari NS, Dorgham K, Sallette J, Sedkaoui SM, AlKhater S, Rigo-Bonnin R, Morandeira F, Roussel L, Vinh DC, Ostrowski SR, Condino-Neto A, Prando C, Bonradenko A, Spaan AN, Gilardin L, Fellay J, Lyonnet S, Bilguvar K, Lifton RP, Mane S; HGID Lab; COVID Clinicians; COVID-STORM Clinicians; NIAID Immune Response to COVID Group; NH-COVAIR Study Group; Danish CHGE; Danish Blood Donor Study; St. James's Hospital; SARS CoV2 Interest group; French COVID Cohort Study Group; Imagine COVID-Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19; Biobank Investigators; COVID Human Genetic Effort; CONSTANCES cohort; 3C-Dijon Study; Cerba Health-Care; Etablissement du Sang study group; Anderson MS, Boisson B, Béziat V, Zhang SY, Vandreakos E, Hermine O, Pujol A, Peterson P, Mogensen TH, Rowen L, Mond J, Debette S, de Lamballerie X, Duval X, Mentré F, Zins M, Soler- Palacin P, Colobran R, Gorochov G, Solanich X, Susen S, Martinez-Picado J, Raoult D, Vasse M, Gregersen PK, Piemonti L, Rodríguez-Gallego C, Notarangelo LD, Su HC, Kisand K, Okada S, Puel A, Jouanguy E, Rice CM, Tiberghien P, Zhang Q, Cobat A, Abel L, Casanova JL. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021 Aug 19;6(62):eabl4340. doi: 10.1126/sciimmunol.abl4340. PMID: 34413139; PMCID: PMC8521484. 8: Forestier E, Roubaud-Baudron C, Fraisse T, Patry C, Gavazzi G, Hoen B, Carauz-Paz P, Moheb-Khosravi B, Delahaye F, Sost G, Paccalin M, Nazeyrollas P, Strady C, Alla F, Selton-Suty C; AEPEI and the GInGer Elderl-IE study group; AEPEI and the GInGer Elderl-IE study group. Comprehensive geriatric assessment in older patients suffering from infective endocarditis. A prospective multicentric cohort study. Clin Microbiol Infect. 2019 Oct;25(10):1246-1252. doi: 10.1016/j.cmi.2019.04.021. Epub 2019 May 2. PMID: 31055167. 9: Martínez-Velilla N, Garrués-Irisarri M, Ibañez-Beroiz B, Gil-Cabañas J, Richarte-García A, Idoate-Saralegui F, de Paz PC, Cambra K. An exercise program with patient's involvement and family support can modify the cognitive and affective trajectory of acutely hospitalized older medical patients: a pilot study. Aging Clin Exp Res. 2016 Jun;28(3):483-90. doi: 10.1007/s40520-015-0434-0. Epub 2015 Sep 2. PMID: 26328517. 10: Krastinova E, Seng R, Lechenadec J, Panjo H, Essat A, Makhloufi D, Obadia M, Bernard L, Goujard C, Meyer L; ANRS PRIMO cohort. Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption? BMC Infect Dis. 2015 Apr 10;15:178. doi: 10.1186/s12879-015-0892-1. PMID: 25888386; PMCID: PMC4403722. 11: Ortega-Loayza AG, Ramos W, Gutierrez EL, Paz PC, Bobbio L, Galarza C. Cutaneous manifestations of internal malignancies in a tertiary health care hospital of a developing country. An Bras Dermatol. 2010 Sep-Oct;85(5):736-42. doi: 10.1590/s0365-05962010000500026. PMID: 21152807. 12: Gutierrez EL, Galarza C, Ramos W, Tello M, De Paz PC, Bobbio L, Barquinero A, Ronceros G, Ortega-Loayza AG. Facial porokeratosis: A series of six patients. Australas J Dermatol. 2010 Aug;51(3):191-4. doi: 10.1111/j.1440-0960.2009.00616.x. PMID: 20695858. 13: Sorrentino R, Morello S, Chen S, Bonavita E, Pinto A. The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation. J Cell Physiol. 2010 Apr;223(1):158-67. doi: 10.1002/jcp.22022. PMID: 20049870.